Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

Clinical trial NCT07371585 · RECRUITING

Trial details

NCT number: NCT07371585
Sponsor: SOLTI Breast Cancer Research Group
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Stage IV

Start date: 2026-02-18
Primary completion: 2029-08-01
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.